DaVita (DVA) has caught investor attention after a strong recent run, with the stock last closing at $196.26. That move sits against a backdrop of steady operations focused on kidney dialysis and related services.

The recent jump in DaVita’s share price, with a 7 day share price return of 26.51% and year to date share price return of 71.39%, sits alongside a 3 year total shareholder return of 105.31%. This indicates momentum that long term holders have already experienced.

If this kind of move has you looking beyond dialysis providers, it could be a good moment to broaden your watchlist and uncover 35 healthcare AI stocks

With DaVita trading at $196.26, a value score of 3, and an intrinsic value estimate that sits at a premium to the current price, you have to ask: is there still a buying opportunity here, or is the market already pricing in future growth?

Most Popular Narrative: 29.4% Overvalued

DaVita’s latest close of $196.26 sits meaningfully above the narrative fair value of $151.71, which is built on detailed earnings, margin and discount rate assumptions.

The analysts have a consensus price target of $151.71 for DaVita based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $190.0, and the most bearish reporting a price target of just $126.0.

Curious what earnings path and margin profile would support that $151.71 figure when the stock trades at $196.26 today? The narrative leans on specific revenue growth, profitability and buyback assumptions that meaningfully reshape per share earnings over time. The tension between those inputs and the required return sits at the heart of this valuation story.

Result: Fair Value of $151.71 (OVERVALUED)

However, that story can still be knocked off course if elevated patient mortality continues to weigh on treatment volumes or if reimbursement updates fail to keep pace with costs.

Another Angle On Valuation

The narrative fair value suggests DaVita is 29.4% overvalued at $196.26, yet the current P/E of 16.7x sits below peers at 32.1x, the US Healthcare average at 22.4x, and an estimated fair ratio of 25.2x. If earnings remain at current levels, this raises the question of whether the market is underestimating this stock or the risks.

Next Steps

With mixed signals on valuation and sentiment, this is a moment to look through the numbers yourself and decide how comfortable you are with the trade off between risk and reward. If you want a clear summary of what the data is flagging on both sides, take a look at the 3 key rewards and 1 important warning sign

Looking for more investment ideas?

If this review has sharpened your thinking, do not stop here. The real edge often comes from comparing opportunities across different types of stocks and themes.

• Spot potential turnaround stories early by checking out 25 elite penny stocks with strong financials that already show credible financial strength instead of just hype.
• Zero in on quality at a reasonable price with the 51 high quality undervalued stocks, so you are not relying on headline moves alone.
• Build a steadier core to your portfolio by using the 72 resilient stocks with low risk scores that focuses on resilience when conditions change.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.